Navigation Links
Aegera Therapeutics welcomes two experienced executives to its board of directors
Date:4/24/2008

MONTREAL, April 24 /PRNewswire/ - Aegera Therapeutics Inc. is very pleased to announce the appointment of two experienced biotechnology and financial executives to its Board of Directors: Mr. Jeremy Curnock Cook, Executive Chairman and Founder of BioScience Managers Limited, and Mr. Gary Littlejohn, Managing Director of Desjardins Securities.

"Gary and Jeremy's extensive industry experience and networks will be critical for Aegera as we make key strategic decisions in support of the attainment of our corporate vision of becoming a profitable, public biotechnology company," commented Mr. James Rae, Chairman of the Board, Aegera Therapeutics Inc.

"I am extremely enthusiastic about joining Aegera's Board at such a critical and exciting time for the company," stated Mr. Curnock Cook. "Their recent clinical and business milestone achievements are very impressive by any measure and I look forward to working with management and the Board to assist the company in accelerating their efforts to achieve their very aggressive business plan."

"Aegera is one of Canada's premier biotechnology companies." added Mr. Littlejohn. "I look forward to working with the accomplished executive team to capitalize on their successes and to continue to build shareholder value both as a private and potentially as a public company."

Mr. Curnock Cook and Mr. Littlejohn join Aegera's existing Board consisting of the following members:

- Mr. James M. Rae, Chairman, President, Remedis Consulting

- Dr. Michael J. Berendt, President & CEO, Aegera Therapeutics

- Dr. Ines Holzbaur, Vice-President, GeneChem Management

- Mr. Serge Langford, Managing Partner, Multiple Capital

- Dr. Luc Marengere, Managing General Partner, Vengrowth Capital

Management

- Mr. Joseph Regan, B.Sc., MBA, Vice President, GrowthWorks Capital

- Mr. Lennie Ryer, B. Comm, CA, CFE, CFO and VP Finance, ConjuChem

The detailed biographies of Mr. Curnock Cook, Mr. Littlejohn and all of Aegera's Board Members can be viewed at http://www.aegera.com

About Aegera Therapeutics Inc.

Aegera Therapeutics is a well funded, clinical stage biotechnology company focused on developing drugs that control apoptosis to address major unmet medical needs. In addition to AEG33773, a compound in Phase 1 clinical development for the treatment of pain associated with diabetic neuropathy, Aegera has three programs in clinical development for oncology indications. Details of our programs can be viewed on our Website at http://www.aegera.com.


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
2. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
3. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
4. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
5. United Therapeutics to Announce First Quarter 2008 Financial Results Before Market Open on Thursday, May 1, 2008
6. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
7. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
8. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
9. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
10. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
11. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
Breaking Biology Technology:
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/9/2016)... in attendance control systems is proud to announce the introduction of fingerprint attendance control ... right employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
Breaking Biology News(10 mins):